Jane Street Group, LLC Oncocyte Corp Transaction History

Jane Street Group, LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$0.2 - $0.49 $3,452 - $8,458	-17,262 Reduced 41.03%	24,806 $8,000
Q4 2022 Feb 14, 2023	BUY	$0.25 - $15.6 $2,836 - $176,997	11,346 Added 36.93%	42,068 $13,000
Q3 2022 Nov 14, 2022	BUY	$0.76 - $15.98 $23,348 - $490,937	30,722 New	30,722 $22,000
Q3 2022 Nov 14, 2022	BUY	$0.76 - $15.98 $23,348 - $490,937	30,722 New	30,722 $22,000
Q2 2021 Aug 16, 2021	SELL	$3.77 - $6.0 $133,838 - $213,006	-35,501 Closed	0 $0
Q1 2021 May 18, 2021	BUY	$2.39 - $6.5 $84,847 - $230,756	35,501 New	35,501 $184,000
Q4 2020 Feb 17, 2021	SELL	$1.38 - $2.63 $25,391 - $48,392	-18,400 Closed	0 $0
Q3 2020 Nov 17, 2020	SELL	$1.2 - $1.89 $39,560 - $62,307	-32,967 Reduced 64.18%	18,400 $26,000
Q2 2020 Aug 17, 2020	BUY	$1.91 - $3.45 $98,110 - $177,216	51,367 New	51,367 $98,000
Q3 2019 Nov 14, 2019	SELL	$1.59 - $2.51 $113,433 - $179,068	-71,342 Closed	0 $0
Q2 2019 Aug 15, 2019	BUY	$2.49 - $5.45 $147,853 - $323,615	59,379 Added 496.36%	71,342 $178,000
Q1 2019 May 16, 2019	BUY	$1.47 - $5.91 $17,585 - $70,701	11,963 New	11,963 $47,000

411K

Ticker OCX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 118,609,000
Market Cap $294M
Description
OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay....

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

Stay updated on Jane Street Group, LLC with notifications on news.